As the most reliable and balanced news aggregation service on the internet, DML News offers the following information published by DailyMail:
A blood pressure drug recalled worldwide amid fears it could cause cancer does not increase the risk of the disease in the short run.
Valsartan, which can be prescribed under the brand name Diovan, was recalled in 22 countries, including the US and UK, in July.
The article goes on to state the following:
A change in manufacturing in China caused N-Nitrosodimethylamine (NDMA) – a potent chemical also used in rocket fuel – to trickled into the supply.
Yet, a Danish study released [Wednesday] found no link between NDMA exposure through valsartan and a person developing cancer over four years.
Researchers from the University of Southern Denmark analysed 5,150 people over 40 with no history of cancer.
The participants had taken valsartan at some point between 2012 and 2017.
Zhejiang Huahai Pharmaceuticals, a company in Linhai, east China, which manufactured the drug, changed its production process in 2012, which is thought to have led to NDMA contamination.
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds fast tracked analysis https://t.co/mRF1KcCWxd with linked commentary https://t.co/jvvtGrggHN pic.twitter.com/V0gWdsEYG5
— The BMJ (@bmj_latest) September 13, 2018
— CNN (@CNN) September 12, 2018
To weigh in on this information provided by DailyMail, engage in our LIVE CHAT below. Scroll down.